# Kriya Therapeutics

Kriya Therapeutics is an other based in Palo Alto, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Palo Alto, United States
- **Region:** North America
- **Address:** Palo Alto, CA, United States
- **Founded:** 2019
- **Assets under management:** Undisclosed
- **Website:** kriyatherapeutics.com
- **LinkedIn:** https://www.linkedin.com/company/kriyatx

## Regulatory record

- **Reports private funds:** No

## About

Kriya is a biopharmaceutical company developing gene therapy to address common diseases that impact millions of people worldwide. Learn more.

## Sectors

- Healthcare Services

## People

- Shankar Ramaswamy — Co-Founder, Chairman and Chief Executive Officer
- Roger Jeffs — Co-Founder and Vice Chairman
- Fraser Wright — Scientific Co-Founder and Chief Gene Therapy Officer
- Sachiyo Minegishi — Chief Financial Officer
- Greg Di Russo — Chief Medical Officer
- Britt Petty — Chief Manufacturing Officer
- Michele Stone — Chief Scientific Officer
- Brian Furmanski — Chief Development Officer
- Mark Chen — Chief Operating Officer
- Katherine Eade — Chief Legal Officer
- C.R. Sincock, II — Founding Investor and Board Observer

## Questions

### Who runs investment decisions at Kriya Therapeutics?

Kriya is a biopharmaceutical company, not an investment firm. The CEO, Shankar Ramaswamy, leads overall strategy. The company is backed by institutional investors including Patient Square Capital and Premji Invest, whose board representatives participate in governance.

### How does Kriya source its therapeutic programs?

Kriya targets diseases with validated biological pathways and high unmet medical need, focusing on ophthalmology, metabolic, and neurologic conditions. Its scientific co-founder Fraser Wright and chief scientific officer Michele Stone lead target selection. The company's advisors include leading gene therapy researchers from Stanford and UMass Medical School.

### Does Kriya manufacture its own gene therapies?

Yes. Kriya has an in-house manufacturing capability led by Chief Manufacturing Officer Britt Petty, who previously oversaw gene therapy manufacturing at AveXis and Biogen. This vertical integration is a deliberate structural choice, distinguishing Kriya from many gene therapy companies that outsource manufacturing.

### What investment stages does Kriya typically target?

Kriya does not make investments; it raises venture capital and private equity for its own pipeline. The company has raised over $900 million since 2019 across seed, multiple follow-on rounds, and later-stage financing.

### What is Kriya's known posture on partnerships and licensing?

Kriya has not publicly disclosed specific licensing deals. The company's website references a board member with experience forming strategic ventures, and its legal team includes IP expertise. The company's strategy emphasizes internal discovery and manufacturing rather than external licensing.

## Related profiles

- [Avisa Partners SAS](https://altss.com/profile/avisa-partners-sas)
- [Dexcel Pharma Technologies Ltd.](https://altss.com/profile/dexcel-pharma-technologies-ltd)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/kriya-therapeutics

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology